share_log

Jones Trading Initiates Coverage On Y-mAbs Therapeutics With Buy Rating, Announces Price Target of $23

Benzinga ·  Jul 12 04:46

Jones Trading analyst Justin Walsh initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and announces Price Target of $23.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment